Abstract
Pharmacovigilance is a scientific discipline that is underrecognized in its importance for improving understanding of drug effects in humans. It excels as a vehicle for detecting safety concerns particularly those early in the post-market phase after prescription drug approval. This is the time in the life cycle of a drug when manufacturers are required by regulatory agencies to provide adverse drug reaction (ADR) reports and the time when clinicians are gaining experience with new agents and are more likely to report ADRs [20]. The reporting of cases of drug-induced harm and subsequent analysis of such data is a critical part of population health surveillance, given the frequency of the use of drug therapy as a medical intervention.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aminkeng F, Amstutz U, Rassekh SR, Dionne F, Hwang S, Rieder MJ, Fung V, Bhavsar AP, Smith A, Brunham L, Ross CJ, Hayden MR, Carleton BC Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity (submitted for publication)
Brock P, Bellman S (1991) Ototoxicity of cisplatinum. Br J Cancer 63(1):159–160
Crozier JA, Swaika A, Moreno-Aspitia A (2014) Adjuvant chemotherapy in breast cancer: to use or not to use, the anthracyclines. World J Clin Oncol 5(3):529–538
Sim SC, Ingelman-Sundberg M (2010) The human cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 4(4):278–281. Retrieved from url http://www.cypalleles.ki.se/cyp2d6.htm
Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351(27):2827–2831
Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23(34):8588–8596
Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13(6):819–829
Kremer LC, van Dalen EC, Offringa M, Voute PA (2002) Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 13(4):503–512
Lam J, Woodall KL, Solbeck P, Ross CJ, Carleton BC, Hayden MR, Koren G, Madadi P (2014) Codeine-related deaths: the role of pharmacogenetics and drug interactions. Forensic Sci Int 239:50–56
Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32(2):302–314
Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton B (2013) CPNDS Clinical Recommendations Group. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol 20(3):e369–e396
McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8(1):10–16
Rassekh SR, Ross CJD, Carleton BC, Hayden MR (2013) Cancer pharmacogenomics in children: research initiatives and progress to date. Paediatr Drugs 15(2):71–81
Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds) (1999) Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. National Cancer Institute, Bethesda
Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR, CPNDS Consortium (2009) Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Gen 14(12):1345–1349
Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC (2014) VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer 61(6):1055–1062
U.S. Department of Health and Human Services, National Institute of Health, National Cancer Institute (2014) Platinum-based treatment for cancer: the discovery of cisplatin. Retrieved from http://www.cancer.gov/research/progress/discovery/cisplatin
van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, Oldenburger F, Koning CC, van Leeuwen FE, Kremer LC (2010) Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 170(14):1247–1255
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710–717
Weber J (1984) Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res 6:1–7
Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115–124
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Carleton, B. (2017). What Is the Future of Pharmacovigilance and How Can We Make It as Good as Possible? . In: Edwards, I., Lindquist, M. (eds) Pharmacovigilance. Adis, Cham. https://doi.org/10.1007/978-3-319-40400-4_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-40400-4_3
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-40399-1
Online ISBN: 978-3-319-40400-4
eBook Packages: MedicineMedicine (R0)